(Reuters) -Eli Lilly hit $1 trillion in market value on Friday, making it the first drugmaker to enter the exclusive club dominated by tech giants and underscoring its rise as a weight-loss powerhouse.
Here are some reactions to Lilly joining the trillion dollar club:
EVAN SEIGERMAN, ANALYST AT BMO CAPITAL MARKETS
"The current valuation points to investor confidence in the longer-term durability of the company's metabolic health franchise. It also suggests that investors prefer Lilly over Novo in the obesity arms race. Taking a step back, we're also seeing money rotate into the sector as investors may be worried about an AI bubble."
HANK SMITH, DIRECTOR & HEAD OF INVESTMENT STRATEGY AT LILLY SHAREHOLDER HAVERFORD TRUST
"Investors have historically liked secure earnings growth and (Eli Lilly) is the only large cap pharma that has that kind of earnings profile."
(Reporting by Siddhi Mahatole and Shashwat Chauhan in Bengaluru; Editing by Leroy Leo)
LATEST POSTS
Home Wellness Basics: Building Your Home Exercise center- 'Pluribus' release date: Everything you need to know about the new series from 'Better Call Saul's' co-creator
- Blue Origin safely launches wheelchair user to space and back
- Most loved Seared Chicken: Which Chain Rules?
- The most effective method to Distinguish the Best Material Organization in Your Space
- Nigeria police charge Joshua driver with dangerous driving over fatal crash
- Instructions to Upgrade the Mechanical Highlights of Your Shrewd Bed for a Superior Night's Rest
- Is 'Stranger Things' releasing one last episode? The 'Conformity Gate' fan theory explained as speculation mounts.
- Inn The executives: A Remunerating Profession Decision for Energetic People
